We have covered BCMA-APRIL approaches in multiple myeloma for a couple of years now and it’s time for a much needed update and look at where this niche is.
Beyond Bluebird’s bb2121 BCMA CAR T cell therapy, there are now a raft of different products across multiple companies including CARs, bispecific antibodies, and even ADCs.
What was a new target three years ago now is rapidly becoming a very crowded space indeed and the pressure will be on companies to differentiate their product in some way, otherwise they risk being a me-too or just another bowl of red chills…
As a new target is validated, it doesn’t take long for another ten companies to immediately try to capitalise on it in the ever increasing race to market with new product development.
Here, we take stock of where things are at.